Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 33, Issue 4, Pages 923-928Publisher
IOS PRESS
DOI: 10.3233/JAD-2012-121393
Keywords
Alzheimer's disease; cerebrospinal fluid; ELISA; tau
Categories
Funding
- Science Foundation Ireland [08/1N.1/B2033]
- Mater College for Postgraduate Education and Research, Dublin
Ask authors/readers for more resources
Elevated cerebrospinal fluid concentrations of tau discriminate Alzheimer's disease from other neurodegenerative conditions. The reasons for this are unclear. While commercial assay kits are widely used to determine total-tau concentrations, little is known about their ability to detect different aggregation states of tau. We demonstrate that the leading commercial enzyme-linked immunosorbent assay reliably detects aggregated and monomeric tau and evinces good recovery of both species when added into cerebrospinal fluid. Hence, the disparity between total-tau levels encountered in Alzheimer's disease and other neurodegenerative conditions is not due to differential recognition of tau assembly forms or the extent of degeneration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available